Melissa E. Quintero

Campinas, SP 13083970, Brazil

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

High-Resolution Magic-Angle-Spinning NMR in Revealing Hepatoblastoma Hallmarks.

High-Resolution Magic-Angle-Spinning NMR in Revealing Hepatoblastoma Hallmarks.

Journal: Biomedicines
Published: November 02, 2022

Metabolomics by NMR Combined with Machine Learning to Predict Neoadjuvant Chemotherapy Response for Breast Cancer.

Metabolomics by NMR Combined with Machine Learning to Predict Neoadjuvant Chemotherapy Response for Breast Cancer.

Journal: Cancers
Published: August 23, 2022

Circulating Metabolites as Biomarkers of Disease in Patients with Mesial Temporal Lobe Epilepsy.

Circulating Metabolites as Biomarkers of Disease in Patients with Mesial Temporal Lobe Epilepsy.

Journal: Metabolites
Published: March 20, 2022

A Metabonomic View on Wilms Tumor by High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance Spectroscopy.

A Metabonomic View on Wilms Tumor by High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance Spectroscopy.

Journal: Diagnostics (Basel, Switzerland)
Published: November 14, 2021

Metabolomics in degenerative brain diseases.

Metabolomics in degenerative brain diseases.

Journal: Brain research
Published: July 10, 2021

A case series of platelet rich plasma in chronic venous ulcers.

A case series of platelet rich plasma in chronic venous ulcers.

Journal: Regenerative therapy
Published: December 01, 2020

Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia.

Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia.

Journal: Advances in experimental medicine and biology
Published: February 13, 2019

GLS2 is protumorigenic in breast cancers.

GLS2 is protumorigenic in breast cancers.

Journal: Oncogene
Published: October 17, 2018

Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.

Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.

Journal: BMC cancer
Published: January 12, 2017
Showing 1-9 of 9

Last Updated: 09/26/2026